Want to see SE:XPC full AI Analyst Report?
Top Page
XP Chemistries AB
(XPC)
Select Model
Select Model
Rating:48Neutral
Price Target:
kr0.21
▲(22.35% Upside)
Action:Reiterated
Date:09/06/26
The score is held down mainly by weak financial performance—large ongoing losses and negative free cash flow—despite the benefit of a debt-free balance sheet. Technicals are supportive with price strength above moving averages and a positive MACD, but overbought RSI/Stoch readings temper the outlook. Valuation is also constrained because profitability is negative (negative P/E) and no dividend yield is available.
Positive Factors
Debt-free balance sheet
A debt-free balance sheet reduces financial risk and avoids interest and refinancing burdens while the company scales. The sizeable equity base provides some resilience against operating volatility, although continued losses could gradually weaken this cushion.
Negative Factors
Persistent net losses
Deep and continuing losses show that the current revenue base does not yet cover the company’s operating cost structure. Persistent negative profitability can erode equity, increase reliance on external funding, and delay the point at which growth translates into sustainable earnings.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-free balance sheet
A debt-free balance sheet reduces financial risk and avoids interest and refinancing burdens while the company scales. The sizeable equity base provides some resilience against operating volatility, although continued losses could gradually weaken this cushion.
Read all positive factors
XP Chemistries AB (XPC) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr65.94M
Dividend YieldN/A
Average Volume (3M)252.95K
Price to Earnings (P/E)―
Beta (1Y)0.63
Revenue GrowthN/A
EPS GrowthN/A
CountrySE
Employees2
SectorGeneral
Sector StrengthN/A
IndustryChemicals
Share Statistics
EPS (TTM)-0.04
Shares Outstanding313,976,300
10 Day Avg. Volume310,990
30 Day Avg. Volume252,951
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)0.97
Price to Sales (P/S)109.05
P/FCF Ratio-3.89
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.03
Revenue Forecast (FY)kr6.03M
XP Chemistries AB Business Overview & Revenue Model
Company Description
As a biotechnology company, XP Chemistries AB specializes in the development and production of forest-derived capsaicin and its related compounds. Its diverse offerings include ingredients for animal nutrition, components for cosmetic formulations...
How the Company Makes Money
null...
XP Chemistries AB Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
54
Neutral
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 320.05K | 327.39K | 283.94K | 663.68K | 1.06M | 279.39K |
| Gross Profit | 226.78K | 127.68K | 328.97K | 335.61K | 488.98K | 149.56K |
| EBITDA | -10.28M | -9.05M | -7.52M | -8.70M | -8.73M | -5.01M |
| Net Income | -9.56M | -8.52M | -7.13M | -8.04M | -7.92M | -4.55M |
Balance Sheet | ||||||
| Total Assets | 33.90M | 38.07M | 22.72M | 27.20M | 30.65M | 34.39M |
| Cash, Cash Equivalents and Short-Term Investments | 9.71M | 15.23M | 2.15M | 7.83M | 15.20M | 21.40M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 1.77M | 1.13M | 1.16M | 1.51M | 1.58M | 3.09M |
| Stockholders Equity | 32.14M | 36.94M | 21.56M | 25.69M | 29.07M | 31.30M |
Cash Flow | ||||||
| Free Cash Flow | -12.34M | -9.18M | -8.53M | -11.41M | -11.80M | -8.13M |
| Operating Cash Flow | -11.68M | -8.85M | -7.69M | -9.08M | -9.85M | -4.99M |
| Investing Cash Flow | -1.30M | -332.30K | -834.96K | -2.33M | -1.95M | -6.31M |
| Financing Cash Flow | 22.47M | 22.26M | 2.85M | 4.04M | 5.60M | 32.70M |
XP Chemistries AB Technical Analysis
Positive
0.17
Price Trends
0.17
Positive
0.17
Positive
0.18
Positive
Market Momentum
<0.01
Negative
65.55
Neutral
71.57
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:XPC, the sentiment is Positive. The current price of 0.17 is below the 20-day moving average (MA) of 0.18, below the 50-day MA of 0.17, and below the 200-day MA of 0.18, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 65.55 is Neutral, neither overbought nor oversold. The STOCH value of 71.57 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:XPC.
XP Chemistries AB Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | kr27.58M | 7.96 | ― | ― | -17.14% | 88.76% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
54 Neutral | kr327.98M | -17.28 | -8.17% | ― | -1.90% | -13.63% | |
49 Neutral | kr419.44M | -32.59 | ― | ― | 54.37% | 52.22% | |
48 Neutral | kr65.94M | -5.37 | ― | ― | ― | ― | |
46 Neutral | kr490.32M | -10.90 | ― | ― | 3.26% | 16.82% | |
43 Neutral | kr269.36M | -6.06 | ― | ― | -40.40% | 6.62% |
* General Sector Average
SE:XPC
XP Chemistries AB
0.20
-0.06
-23.60%
SE:NEXAM
Nexam Chemical Holding AB
3.19
-0.81
-20.25%
SE:ENZY
Enzymatica AB
2.10
-0.22
-9.48%
SE:IMPC
Impact Coatings AB
2.49
-1.32
-34.71%
SE:CLBIO
Corline Biomedical AB
16.20
1.30
8.72%
SE:PCAT
Photocat A/S
4.50
-3.50
-43.75%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.